01 / DESIGN
What was studied?
A blinded phase 3 study compared cagrilintide-semaglutide with placebo over forty weeks in adults inadequately controlled through diet and exercise.
02 / FINDINGS
What did the researchers report?
The combination produced greater glycated-hemoglobin reductions than placebo. Body-weight change was secondary; adverse events were interpreted within the combination's clinical trial program.
03 / LIMITS
How should it be interpreted?
The intervention contained two defined medicines. Findings cannot be attributed entirely to cagrilintide or transferred to a separately sourced mixture without formulation-specific evidence.
Loti Labs Peptide editorial reading note. Based on the linked source record. Methods and corrections.